(MoneyNewsWire.Net, January 29, 2014 ) Boston, MA - Hoffman Michael B, Director 10% owner of Onconova Therapeutics, Inc. (Nasdaq: ONTX) bought 51,178 shares of Onconova Therapeutics, Inc. from the open market on 01/27/2014 according to an SEC filing reported by insidercow.com at 01/27/2014 09:40:09 PM ET. The stock was up 13.03% after the InsiderCow.com report.
Trade amount: 51,178 Shares
Trade type: Open Market Buy
Price Range: 12.30 - 13.57
Transaction details can be found at http://www.insidercow.com/history/company.jsp?company=ONTX Get real-time alert on any insider trading information from www.insidercow.com, one step before everybody else.
About InsiderCow.com
InsiderCow.com is a leading real-time insider trading information provider. InsiderCow.com is the online division of InsiderCow, a privately-owned company specialized in insider trading information. InsiderCow uses its proprietary software to gather and analyze information provided by the U.S. Securities and Exchange Commission, in real-time. For more information about InsiderCow.com, visit www.insidercow.com.
About ONTX:
"Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company,
focuses on discovering and developing small molecule drug candidates to
treat cancer. Its products include Rigosertib intravenous (IV) that is
in Phase III trials for higher risk myelodysplastic syndromes (MDS);
Rigosertib Oral, which is Phase II clinical trials for patients with
transfusion-dependent lower risk MDS and in patients with head and neck
cancers; and Rigosertib IV, a combination therapy with gemcitabine in a
Phase III clinical trials for the treatment of patients with metastatic
pancreatic cancer."
Disclosure: Insidercow.com is not a registered investment adviser or broker/dealer. Insidercow.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable.
InsiderCow
Kevin Leng
781-526-8657
support@insidercow.com
Source: EmailWire.Com
|